SG11201806121PA - Ror2 antibody compositions and related methods - Google Patents

Ror2 antibody compositions and related methods

Info

Publication number
SG11201806121PA
SG11201806121PA SG11201806121PA SG11201806121PA SG11201806121PA SG 11201806121P A SG11201806121P A SG 11201806121PA SG 11201806121P A SG11201806121P A SG 11201806121PA SG 11201806121P A SG11201806121P A SG 11201806121PA SG 11201806121P A SG11201806121P A SG 11201806121PA
Authority
SG
Singapore
Prior art keywords
international
ror2
jupiter
pct
antibody
Prior art date
Application number
SG11201806121PA
Inventor
Christoph Rader
Haiyong Peng
Xiuling Li
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG11201806121PA publication Critical patent/SG11201806121PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111010111011101101011111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number ..... ...1 (43) International Publication Date WO 2017/127702 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07K 16/28 (2006.01) C07K 14/725 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/014370 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 20 January 2017 (20.01.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/280,834 20 January 2016 (20.01.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: THE SCRIPPS RESEARCH INSTITUTE TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [US/US]; 10550 North Torrey Pines Road, La Jolla, CA TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 92037 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: RADER, Christoph; 144 Victorian Lane, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CL CM, GA, GN, GQ, Jupiter, FL 33458 (US). PENG, Haiyong; 1200 Town Cener, #312, Jupiter, FL 33458 (US). LI, Xiuling; 853 GW, KM, ML, MR, NE, SN, TD, TG). University Blvd., #202, Jupiter, FL 33458 (US). Published: Agents: FITTING, Thomas et al.; The Scripps Research — with international search report (Art. 21(3)) (74) Institute, 10550 North Torrey Pine Road, TPC-8, La Jolla, with sequence listing part of description (Rule 5.2(a)) CA 92037 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) = Title: ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (54) ROR2 mAbs V R 19t1 C^3R1 FR2 CDa 193 CUE43 PII4 GM TOT, 4 % V„ Il ei © IN IN ei ,-1 FIG. 1 IN 1-1 (57) : The disclosure provides antibodies, antibody fragments or antigen- binding fragments, as well as related antibody N drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2, Also provided in the dis - closure are methods of using such antibodies in various diagnostic and therapeutic applications, 0
SG11201806121PA 2016-01-20 2017-01-20 Ror2 antibody compositions and related methods SG11201806121PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662280834P 2016-01-20 2016-01-20
PCT/US2017/014370 WO2017127702A1 (en) 2016-01-20 2017-01-20 Ror2 antibody compositions and related methods

Publications (1)

Publication Number Publication Date
SG11201806121PA true SG11201806121PA (en) 2018-08-30

Family

ID=57915184

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806121PA SG11201806121PA (en) 2016-01-20 2017-01-20 Ror2 antibody compositions and related methods

Country Status (10)

Country Link
US (2) US11078273B2 (en)
EP (1) EP3405494A1 (en)
JP (1) JP2019509023A (en)
KR (1) KR20180099887A (en)
CN (1) CN109311982A (en)
AU (1) AU2017209313A1 (en)
CA (1) CA3011817A1 (en)
IL (1) IL260688A (en)
SG (1) SG11201806121PA (en)
WO (1) WO2017127702A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180099887A (en) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 ROR2 antibody compositions and related methods
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
WO2019204564A1 (en) * 2018-04-18 2019-10-24 Exelixis, Inc. Anti-ror antibody constructs
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
CN111378040B (en) * 2018-12-29 2021-08-10 深圳大学 Antibody for detecting multiple malignant tumor cells and application thereof
CN111378039B (en) * 2018-12-29 2021-08-24 深圳大学 Antibody for treating malignant tumor and application thereof
WO2020143506A1 (en) * 2019-01-08 2020-07-16 深圳大学 Detection of malignant tumor cells antibodies and uses thereof
WO2021102055A1 (en) * 2019-11-18 2021-05-27 The Regents Of The University Of California Anti-ror-2 antibodies and methods of use
CA3175055A1 (en) 2020-03-13 2021-09-16 Julius-Maximilians-Universitat Wurzburg Affinity matured and humanized binding domains targeting ror2
WO2021202807A1 (en) * 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
WO2022270396A1 (en) * 2021-06-21 2022-12-29 株式会社Epsilon Molecular Engineering Double-screening method
TW202342537A (en) * 2022-02-25 2023-11-01 美商拜奧亞特拉公司 Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US20140322234A1 (en) 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
PT2692865E (en) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Transposition-mediated identification of specific binding or functional proteins
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
JP6463029B2 (en) * 2013-08-02 2019-01-30 有未 伊谷 Monoclonal antibody specifically recognizing human mesenchymal stem cells and method for isolating and / or evaluating quality of human mesenchymal stem cells using the same
RU2744836C2 (en) 2014-05-08 2021-03-16 Новодиакс, Инк. Direct immunohistochemical analysis
CN105233291A (en) * 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
SG10202101603TA (en) 2014-12-23 2021-03-30 Nbe Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
FR3030807B1 (en) 2014-12-23 2018-02-02 Thales NON-LINEAR METHOD OF ESTIMATING A MIXTURE OF SIGNALS
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
CA2983293C (en) 2015-04-24 2023-06-20 The Regents Of The University Of California Modulators of ror1-ror2 binding
KR20180099887A (en) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 ROR2 antibody compositions and related methods

Also Published As

Publication number Publication date
US11834501B2 (en) 2023-12-05
JP2019509023A (en) 2019-04-04
KR20180099887A (en) 2018-09-05
WO2017127702A1 (en) 2017-07-27
IL260688A (en) 2018-10-31
CN109311982A (en) 2019-02-05
CA3011817A1 (en) 2017-07-27
US20190031754A1 (en) 2019-01-31
US11078273B2 (en) 2021-08-03
US20210347892A1 (en) 2021-11-11
AU2017209313A1 (en) 2018-08-09
EP3405494A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201806120WA (en) Ror1 antibody compositions and related methods
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806496SA (en) Antigen binding proteins that bind pd-l1